Stocktwits on MSN
SentinelOne stock rises after Citron Research flags AI security opportunity amid Clawdbot buzz
Citron Research said in a post on X that while SentinelOne is being priced like a dead legacy endpoint vendor, its ...
Citron Research has ignited a fresh debate at the intersection of crypto regulation, competition, and Wall Street power by publicly backing tokenization firm Securitize while sharply criticizing ...
Tokenization platform Securitize is going public — as soon as the first half of 2026 — through a SPAC deal with Cantor Equity ...
Citron’s bullish stance comes as the cybersecurity industry grapples with new challenges presented by autonomous AI agents, ...
SentinelOne Inc (NASDAQ: S) shares are rising Tuesday after a social media post from Citron Research highlighted a ...
Teladoc Health Inc (NYSE:TDOC) shares are rising Monday after Citron Research made positive comments about the company on its X account. What Happened: Citron posted on X Monday morning that it ...
SentinelOne (S) rose 4% after a bullish post from Citron Research. "SentinelOne is time to pound the table," Citron wrote in a posting on X on Tuesday. "Clawdbot is the tell- Autonomous Agents, the ...
Citron Research identified Teladoc as a potential AI opportunity hiding in plain sight. While Teladoc's revenue has plateaued, its profitability has grown. The stock is quite cheap compared to ...
Following a sharp rally in the previous session, Teladoc Health (NYSE:TDOC) added ~5% in the premarket on Tuesday after Citron Research issued a bullish report on the telehealth firm, arguing that it ...
Citron Research stated in a post to X: “Citron pounding the table that $NBIS is poised to be the next AI Wall Street darling. A sleeper with no analyst coverage yet ...
Citron Research sees Teladoc as a bargain ready to rip higher, citing the end of this government shutdown as a bullish catalyst. While Citron's favorite catalyst seems questionable, Teladoc's bargain ...
Mallinckrodt Pharmaceuticals’ stock plummeted by more than 25 percent Monday after stock commentary firm Citron Research tweeted about the company. Mallinckrodt Pharmaceuticals’ stock plummeted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results